Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2025-01-07 00:00:00 ET · period of report 2024-12-13 · accession 0001415889-25-001007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-01-07 | 2024-12-13+ | ELVN | Hohl Benjamin | CFO | M - OptEx | $2.48 | +14.0K | 14.0K | New | +$34.7K |
| D | 2025-01-07 | 2025-01-03 | ELVN | Hohl Benjamin | CFO | S - Sale+OE | $25.04 | -1,000 | 13.0K | -7% | -$25.0K |
| DM | 2025-01-07 | 2024-12-13+ | ELVN | Hohl Benjamin | CFO | M - OptEx | $0.00 | -14.0K | 155.6K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-13 | M | A | 13,000 | $2.48 | 13,000 | D | — | — | |
| 2 | Common | Common Stock | 2025-01-03 | S | D | 1,000 | $25.04 | 13,000 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $25.00 to $25.045. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 3 | Common | Common Stock | 2025-01-03 | M | A | 1,000 | $2.48 | 14,000 | D | — | — | |
| 4 | Derivative | Stock Option (right to buy) | 2025-01-03 | M | D | 1,000 | $0.00 | 150,306 | D | $2.48 · — to 2031-08-02 | 1,000 Common Stock | (F5) The number of derivative securities beneficially owned following the option exercise is as of January 3, 2025 and reflects the option exercise that occurred December 13, 2024, and reported herein, and subsequent option exercises that occurred on December 27, 2024 and December 30, 2024 as reported in a Form 4 filed by the Reporting Person on December 31, 2024 (F3) The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. |
| 5 | Derivative | Stock Option (right to buy) | 2024-12-13 | M | D | 13,000 | $0.00 | 155,556 | D | $2.48 · — to 2031-08-02 | 13,000 Common Stock | (F4) The number of derivative securities beneficially owned following the option exercise was as of December 13, 2024 and does not reflect subsequent option exercises that occurred on December 27, 2024 and December 30, 2024 as reported in a Form 4 filed by the Reporting Person on December 31, 2024. (F3) The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. |